Original articles

Part 2: Breast implant-associated anaplastic large-cell lymphoma: Recommendations for future research on prevention

C L Kulenkampff, W G Kleintjes


Background. Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a newly defined clinical entity. However, much of the research around this topic is based on low levels of evidence prognostic studies. Part 2 follows on our part 1 article discussion on potential BIA-ALCL risk factors, and provides clinically relevant suggestions for further study.

Recommendations. From the available research, we were able to identify several potential strategies to reduce BIA-ALCL risk. These recommendations were graded according to the grade practice recommendations suggested by Burns et al. These strategies include: avoiding Allergan BIOCELL textured implants; using sterile surgical technique; patient screening; use of anti-inflammatory drugs; and the avoidance of implants in genetically susceptible individuals.

Conclusion. Owing to the lack of studies with a high level of evidence on BIA-ALCL prevention, few strong recommendations for clinical application can be made at this point. However, our article identifies areas in need of further study.

Authors' affiliations

C L Kulenkampff, Department of General Surgery, Cecilia Makiwane Hospital, East London, South Africa

W G Kleintjes, Western Cape Provincial Tertiary Adult Burn Unit, Division of Surgery, Tygerberg Hospital and Stellenbosch University, Cape Town, South Africa

Full Text

 Subscribers Only

Cite this article

South African Journal of Plastic & Reconstructive Aesthetic Surgery & Burns 2020;3(1):20. DOI:10.7196/SAJPRASB.2020.v3i1.37

Article History

Date submitted: 2020-05-19
Date published: 2020-05-19

Article Views

Abstract views: 1471
Full text views: 4

Comments on this article

*Read our policy for posting comments here